Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2026
Proof of Concept, Feasibility, and Safety of Local Anticholinesterase Treatment for Neuromodulator-Induced Facial Muscle Paralysis.
СтатьяКлиническое исследование I фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yoelin Steve, Pot Sera, Tom Courtney, Lam Justine, Kalanski Sophia, Harrington Grace, Shah Sameer B, Carruthers Jean, Gardner Mary
Аннотация
BACKGROUND: As yet, there is no functional focal reverser for the adverse effects of cosmetic botulinum toxin injections.
OBJECTIVE: The authors report the first Phase 1 study in human subjects of local administration of an anticholinesterase for reversing muscle weakness, which may result from these neurotoxin-induced complications.
MATERIALS AND METHODS: An anticholinesterase, or cholinesterase inhibitor, indicated for reversal of neuromuscular blockage in anesthesia, was injected into the same 5 injection sites as were used for the cosmetic onabotulinum toxinA, glabellar treatment.
RESULTS: In most patients treated with the reversal agent under investigation, there was a notable recovery of cosmetic blockade; no subject treated with placebo demonstrated a reversal response. Evidence of reversal became evident within the first 15 minutes after injection of the study drug, with no major or persistent adverse events.
CONCLUSION: Proof of concept, feasibility, and safety of local neuromodulator reversal are now shown; however, further studies are required to optimize dosage, distribution, and formulation.
OBJECTIVE: The authors report the first Phase 1 study in human subjects of local administration of an anticholinesterase for reversing muscle weakness, which may result from these neurotoxin-induced complications.
MATERIALS AND METHODS: An anticholinesterase, or cholinesterase inhibitor, indicated for reversal of neuromuscular blockage in anesthesia, was injected into the same 5 injection sites as were used for the cosmetic onabotulinum toxinA, glabellar treatment.
RESULTS: In most patients treated with the reversal agent under investigation, there was a notable recovery of cosmetic blockade; no subject treated with placebo demonstrated a reversal response. Evidence of reversal became evident within the first 15 minutes after injection of the study drug, with no major or persistent adverse events.
CONCLUSION: Proof of concept, feasibility, and safety of local neuromodulator reversal are now shown; however, further studies are required to optimize dosage, distribution, and formulation.